Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.
Company Growth (employees)
San Diego, US
Size (employees)
22 (est)+5%
Ligand Pharmaceuticals is headquartered in San Diego, US

Key People at Ligand Pharmaceuticals

John L. Higgins

John L. Higgins

John P. Sharp

John P. Sharp

David J. Mangelsdorf

David J. Mangelsdorf

Team Member
Ronald M. Evans

Ronald M. Evans

Team Member
Richard Heyman

Richard Heyman

Vice President of Research

Ligand Pharmaceuticals Office Locations

Ligand Pharmaceuticals has office in San Diego
San Diego, US

Ligand Pharmaceuticals Metrics

Ligand Pharmaceuticals Summary

Market capitalization

$2.2 b

Closing share price

Ligand Pharmaceuticals's current market capitalization is $2.2 b.

Ligand Pharmaceuticals Financials

Ligand Pharmaceuticals's revenue is $49 m in FY, 2013 which is a 24.1% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$49 m$64.5 m$71.9 m$109 m

Revenue growth, %


Gross profit

$43.2 m$55.4 m$66.1 m

Operating expense total

$34 m$44.9 m$44.6 m


$14.9 m$19.6 m$27.3 m

Net Income

$11.4 m$10.9 m$254.9 m($1.6 m)

Operating cash flow

($742 k)$148.6 m($62.8 m)

Ligand Pharmaceuticals Market Value History

We estimate that Ligand Pharmaceuticals's current employees are approximately 100% male

Ligand Pharmaceuticals Online Presence

Ligand Pharmaceuticals News

Ligand Pharmaceuticals Company Life

You may also be interested in